Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Public ClinicalTrials.gov record NCT01369849. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase I/II Study of the Combination of Bendamustine, Rituximab and MK-2206 in the Treatment of Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase I/II trial studies the side effects and best dose of v-akt murine thymoma viral oncogene homolog 1 (Akt) inhibitor MK2206 when given together with bendamustine hydrochloride and rituximab and to see how well they work in treating patients with refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. Akt inhibitor MK2206 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as bendamustine hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving Akt inhibitor MK2206 with bendamustine hydrochloride and rituximab may be an effective treatment for relapsed chronic lymphocytic leukemia or small lymphocytic lymphoma.
Study identification
- NCT ID
- NCT01369849
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 15 participants
Conditions and interventions
Conditions
Interventions
- Akt Inhibitor MK2206 Drug
- Bendamustine Hydrochloride Drug
- Laboratory Biomarker Analysis Other
- Rituximab Biological
Drug · Other · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 2011 (Type not available)
- Primary completion
- Feb 2014 (Actual)
- Completion
- Feb 2014 (Actual)
- Last update posted
- Sep 15, 2017
2011 – 2014
United States locations
- U.S. sites
- 44
- U.S. states
- 5
- U.S. cities
- 32
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic in Arizona | Scottsdale | Arizona | 85259 | — |
| Siouxland Regional Cancer Center | Sioux City | Iowa | 51101 | — |
| Mercy Medical Center-Sioux City | Sioux City | Iowa | 51104 | — |
| Saint Luke's Regional Medical Center | Sioux City | Iowa | 51104 | — |
| Essentia Health Saint Joseph's Medical Center | Brainerd | Minnesota | 56401 | — |
| Fairview Ridges Hospital | Burnsville | Minnesota | 55337 | — |
| Mercy Hospital | Coon Rapids | Minnesota | 55433 | — |
| Essentia Health Cancer Center | Duluth | Minnesota | 55805 | — |
| Essentia Health Saint Mary's Medical Center | Duluth | Minnesota | 55805 | — |
| Miller-Dwan Hospital | Duluth | Minnesota | 55805 | — |
| Fairview-Southdale Hospital | Edina | Minnesota | 55435 | — |
| Unity Hospital | Fridley | Minnesota | 55432 | — |
| Hutchinson Area Health Care | Hutchinson | Minnesota | 55350 | — |
| Minnesota Oncology Hematology PA-Maplewood | Maplewood | Minnesota | 55109 | — |
| Saint John's Hospital - Healtheast | Maplewood | Minnesota | 55109 | — |
| Abbott-Northwestern Hospital | Minneapolis | Minnesota | 55407 | — |
| Hennepin County Medical Center | Minneapolis | Minnesota | 55415 | — |
| North Memorial Medical Health Center | Robbinsdale | Minnesota | 55422 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Metro-Minnesota NCI Community Oncology Research Program | Saint Louis Park | Minnesota | 55416 | — |
| Park Nicollet Clinic - Saint Louis Park | Saint Louis Park | Minnesota | 55416 | — |
| Regions Hospital | Saint Paul | Minnesota | 55101 | — |
| United Hospital | Saint Paul | Minnesota | 55102 | — |
| Saint Francis Regional Medical Center | Shakopee | Minnesota | 55379 | — |
| Lakeview Hospital | Stillwater | Minnesota | 55082 | — |
| Ridgeview Medical Center | Waconia | Minnesota | 55387 | — |
| Rice Memorial Hospital | Willmar | Minnesota | 56201 | — |
| Minnesota Oncology and Hematology PA-Woodbury | Woodbury | Minnesota | 55125 | — |
| Adena Regional Medical Center | Chillicothe | Ohio | 45601 | — |
| Riverside Methodist Hospital | Columbus | Ohio | 43214 | — |
| Columbus CCOP | Columbus | Ohio | 43215 | — |
| Grant Medical Center | Columbus | Ohio | 43215 | — |
| Mount Carmel Health Center West | Columbus | Ohio | 43222 | — |
| Doctors Hospital | Columbus | Ohio | 43228 | — |
| Grady Memorial Hospital | Delaware | Ohio | 43015 | — |
| Fairfield Medical Center | Lancaster | Ohio | 43130 | — |
| Marietta Memorial Hospital | Marietta | Ohio | 45750 | — |
| Knox Community Hospital | Mount Vernon | Ohio | 43050 | — |
| Licking Memorial Hospital | Newark | Ohio | 43055 | — |
| Southern Ohio Medical Center | Portsmouth | Ohio | 45662 | — |
| Springfield Regional Medical Center | Springfield | Ohio | 45505 | — |
| Saint Ann's Hospital | Westerville | Ohio | 43081 | — |
| Genesis HealthCare System | Zanesville | Ohio | 43701 | — |
| Rapid City Regional Hospital | Rapid City | South Dakota | 57701 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01369849, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 15, 2017 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01369849 live on ClinicalTrials.gov.